文献速递白血病

年轻成人急性髓系白血病中NPM1突变等位基因负荷的临床影响分析

Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia.
PubMed 文献 · Br J Haematol · 2019-10-08

该研究在876例入组英国国家试验的NPM1突变急性髓系白血病患者中,分析NPM1突变等位基因负荷的临床影响。单变量分析显示高负荷与较低完全缓解率、较高复发率和较差总生存相关,但多变量分析中该影响大幅减弱,主要归因于合并FLT3内部串联重复等已知不良因素。结论认为应继续使用NPM1突变二元状态联合诱导后微小残留病水平指导治疗,而非按突变负荷分层。

要点

  • 高NPM1突变负荷在单变量中与较差结局相关,但多变量中影响大幅减弱。
  • 高负荷的不良影响主要归因于合并FLT3内部串联重复等已知危险因素。
  • 是否接受首次完全缓解后异基因移植,不影响NPM1突变负荷的效应。

核心结论

  • 应继续使用NPM1突变的有无联合诱导后微小残留病水平指导治疗管理,而非根据NPM1突变等位基因水平进行分层。

研究设计与样本

  • 在876例入组英国国家试验的NPM1突变急性髓系白血病患者中开展的较大规模研究。

主要发现

  • 单变量分析中,较高的NPM1突变等位基因负荷与较低的完全缓解率、较高的复发率和较差的总生存相关。
  • 上述关联在很大程度上归因于高NPM1突变负荷与其它已知不良风险因素(尤其是合并FLT3内部串联重复)的相关性。
  • 多变量分析中,NPM1突变负荷对完全缓解率无显著影响;对复发和总生存的影响虽仍显著但大幅减弱。
  • 在首次完全缓解后接受或未接受异基因移植的患者中,该影响相似。

临床怎么用

  • 临床治疗决策应依据NPM1突变的有无以及诱导治疗后微小残留病水平,而非NPM1突变等位基因负荷。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although an NPM1 mutation is generally considered to be a good prognostic marker in acute myeloid leukaemia, it has recently been suggested that a higher level of NPM1 mutant (NPM1MUT ) alleles relative to wild-type alleles is associated with poor clinical outcome. We therefore sought to confirm this finding in a larger study of 876 NPM1MUT cases entered into UK national trials. In univariate analysis, the higher NPM1MUT allele burden was associated with a lower complete remission (CR) rate, higher relapse rate and reduced overall survival, but this was largely attributable to the association of the higher NPM1MUT allele burden with other known poor risk factors, particularly the presence of a concomitant FLT3 internal tandem duplication. In multivariate analysis, there was no significant impact of the NPM1MUT allele burden on CR rates, and the impact on relapse and overall survival, whilst still significant, was greatly reduced. This impact was similar in patients who did or did not receive an allogeneic transplant in first CR. We conclude that the binary presence or absence of an NPM1 mutation, combined with minimal residual disease levels following induction therapy, should continue to be used in therapeutic management rather than stratification according to the NPM1MUT level.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Linch DC, Hills RK, Burnett AK, et al. Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia. Br J Haematol. 2019. PMID: 31595497. doi:10.1111/bjh.16239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。